Vivek Garipalli - 07 Jan 2026 Form 4 Insider Report for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Role
Director, 10%+ Owner
Signature
/s/Peter J. Rivas as attorney-in-fact for Vivek Garipalli
Issuer symbol
CLOV
Transactions as of
07 Jan 2026
Net transactions value
-$4,288,908
Form type
4
Filing time
09 Jan 2026, 16:08:11 UTC
Previous filing
08 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Garipalli Vivek Director, 10%+ Owner C/O CLOVER HEALTH INVESTMENTS, CORP., NOT APPLICABLE, WILMINGTON /s/Peter J. Rivas as attorney-in-fact for Vivek Garipalli 09 Jan 2026 0001839260

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLOV Class A Common Stock Options Exercise $0 +1,655,949 +89% $0.000000 3,512,196 07 Jan 2026 Direct F1, F2
transaction CLOV Class A Common Stock Tax liability $4,288,908 -1,655,949 -47% $2.59 1,856,247 07 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLOV Restricted Stock Unit Options Exercise -3,342,699 -100% 0 07 Jan 2026 Class B Common Stock 3,342,699 Direct F1, F3
transaction CLOV Class B Common Stock Options Exercise +3,342,699 +48% 10,247,042 07 Jan 2026 Class A Common Stock 3,342,699 Direct F1, F2
transaction CLOV Class B Common Stock Options Exercise -1,655,949 -16% 8,591,093 07 Jan 2026 Class A Common Stock 1,655,949 Direct F1, F2
holding CLOV Class B Common Stock 72,084,543 07 Jan 2026 Class A Common Stock 75,694,143 Held by NJ Healthcare Investments, LLC F1, F4
holding CLOV Class B Common Stock 11,500,000 07 Jan 2026 Class A Common Stock 11,500,000 Held by Ceasar Clover, LLC F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer.
F2 On January 7, 2026, the final 20% of the original number of restricted stock units ("RSUs") in respect of a Class B Common Stock granted to the Reported Person on January 7, 2021 vested, with 1,686,750 shares of the Issuer's Class B Common Stock being delivered to the Reporting Person and 1,655,949 shares of the Issuer's Class B Common Stock automatically converting into an equal number of shares of the Issuer's Class A Common Stock and being withheld by the Issuer to cover the Reporting Person's tax obligations in connection with the vesting event.
F3 Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration. The RSU award vested in equal installments on the first five anniversaries of January 7, 2021.
F4 The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC and Caesar Clover, LLC.